Last updated on February 2018

Ziv-aflibercept Efficacy in Better Regulating AMD


Brief description of study

This is a randomized, open-label, interventional, controlled study to determine the effects of Zaltrap on Neovascularized Wet Macular Degeneration as compared to the control anti-vascular endothelial growth factor ("anti-VEGF") injections (bevacizumab, ranibizumab, or aflibercept).

Clinical Study Identifier: NCT03423823

Contact Investigators or Research Sites near you

Start Over

Principal Investigator, MD

Wagner Macula & Retina Center
Virginia Beach, VA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.